PMID- 21179025
OWN - NLM
STAT- MEDLINE
DCOM- 20110331
LR  - 20211203
IS  - 1744-4292 (Electronic)
IS  - 1744-4292 (Linking)
VI  - 6
DP  - 2010 Dec 21
TI  - A comprehensive map of the mTOR signaling network.
PG  - 453
LID - 10.1038/msb.2010.108 [doi]
AB  - The mammalian target of rapamycin (mTOR) is a central regulator of cell growth 
      and proliferation. mTOR signaling is frequently dysregulated in oncogenic cells, 
      and thus an attractive target for anticancer therapy. Using CellDesigner, a 
      modeling support software for graphical notation, we present herein a 
      comprehensive map of the mTOR signaling network, which includes 964 species 
      connected by 777 reactions. The map complies with both the systems biology markup 
      language (SBML) and graphical notation (SBGN) for computational analysis and 
      graphical representation, respectively. As captured in the mTOR map, we review 
      and discuss our current understanding of the mTOR signaling network and highlight 
      the impact of mTOR feedback and crosstalk regulations on drug-based cancer 
      therapy. This map is available on the Payao platform, a Web 2.0 based 
      community-wide interactive process for creating more accurate and 
      information-rich databases. Thus, this comprehensive map of the mTOR network will 
      serve as a tool to facilitate systems-level study of up-to-date mTOR network 
      components and signaling events toward the discovery of novel regulatory 
      processes and therapeutic strategies for cancer.
FAU - Caron, Etienne
AU  - Caron E
AD  - Institute for Research in Immunology and Cancer, Universite de Montreal, 
      Montreal, Canada.
FAU - Ghosh, Samik
AU  - Ghosh S
FAU - Matsuoka, Yukiko
AU  - Matsuoka Y
FAU - Ashton-Beaucage, Dariel
AU  - Ashton-Beaucage D
FAU - Therrien, Marc
AU  - Therrien M
FAU - Lemieux, Sebastien
AU  - Lemieux S
FAU - Perreault, Claude
AU  - Perreault C
FAU - Roux, Philippe P
AU  - Roux PP
FAU - Kitano, Hiroaki
AU  - Kitano H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Mol Syst Biol
JT  - Molecular systems biology
JID - 101235389
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - *Gene Regulatory Networks
MH  - Humans
MH  - Models, Biological
MH  - Neoplasms/drug therapy
MH  - *Protein Interaction Mapping
MH  - *Signal Transduction
MH  - Sirolimus/pharmacology/therapeutic use
MH  - Systems Biology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC3018167
COIS- The authors declare that they have no conflict of interest.
EDAT- 2010/12/24 06:00
MHDA- 2011/04/01 06:00
PMCR- 2010/12/21
CRDT- 2010/12/24 06:00
PHST- 2010/07/13 00:00 [received]
PHST- 2010/11/12 00:00 [accepted]
PHST- 2010/12/24 06:00 [entrez]
PHST- 2010/12/24 06:00 [pubmed]
PHST- 2011/04/01 06:00 [medline]
PHST- 2010/12/21 00:00 [pmc-release]
AID - msb2010108 [pii]
AID - 10.1038/msb.2010.108 [doi]
PST - ppublish
SO  - Mol Syst Biol. 2010 Dec 21;6:453. doi: 10.1038/msb.2010.108.